Lilly/Amylin submit exenatide
This article was originally published in Pharmaceutical Approvals Monthly
Lilly/Amylin plan to position their type 2 diabetes agent exenatide for use in patients not achieving goal on oral agents; an NDA for the first-in-class incretin mimetic was submitted June 30. "The initial target population for exenatide does not include patients on insulin," Lilly says. Based on exenatide's novel mechanism, the firms are highlighting its potential as an insulin alternative "that carries a lower risk of hypoglycemia with no weight gain." A National Institutes of Health-sponsored study of exenatide in type 1 diabetes is underway. "The results of that [20-month] exploratory study will determine our next steps in the type 1 diabetes arena," Lilly says...
You may also be interested in...
Lilly/Amylin Byetta clears FDA as first incretin mimetic; GSK readies Boostrix launch following May 3 BLA approval. GlaxoSmithKline’s dopamine agonist Requip (ropinirole) is approved May 4 as the first treatment for restless legs syndrome. More FDA approvals in brief
Highlights of NME class of 2005 could be advances in diabetes, with Lilly/Amylin’s exenatide and Amylin’s Symlin currently being reviewed and Pfizer’s inhaled insulin Exubera slated for filing early in the year. Other major pending NMEs include J&J’s dapoxetine for premature ejaculation and Solvay’s irritable bowel syndrome agent Calmactin (cilansetron)
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.